OncoMatch/Clinical Trials/NCT05669820
Antisecretory Factor Glioblastoma Phase 2
Is NCT05669820 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for glioblastoma.
This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: surgical resection
Surgical treatment-resection.
Cannot have received: surgical biopsy only
Only surgical biopsy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify